Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Prostatic Neoplasms 4Lymphoma, Non-Hodgkin 3Lymphoma 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Stomach Neoplasms 2Rectal Neoplasms 2Lymphoma, B-Cell 2Leukemia 2Carcinoma in Situ 2Burkitt Lymphoma 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Triple Negative Breast Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Papillomavirus Infections 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mesothelioma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1

Interventions

Filgrastim 13Cyclophosphamide 13Etoposide 12Doxorubicin 11fludarabine phosphate 10Vincristine 10Cyclosporine 10Peripheral Blood Stem Cell Transplantation 9Radiotherapy 8Prednisone 8Vinblastine 6Tacrolimus 6Rituximab 6Methotrexate 6Gemcitabine 6Bleomycin 6tanespimycin 5Vorinostat 5Ipilimumab 5Bortezomib 5temsirolimus 4Sirolimus 4Nivolumab 4Mycophenolic Acid 4Melphalan 4Magnetic Resonance Spectroscopy 4Ifosfamide 4Dacarbazine 4Cytarabine 4CTLA-4 Antigen 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Hodgkin Disease × Magnetic Resonance Imaging × Clear all
NCT02356159 2025-09-30

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
34 enrolled 18 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡